Company

About

CHA Bio Group

CHA Bio Group

335 pangyoro bundanggu, seongnam, korea

CHA Bio Group is continuing its challenge to become the best in various initial achievements in the bio and healthcare fields. We are developing and producing advanced biopharmaceuticals, including cell and gene therapy products and vaccines, based on our global R&D capabilities, such as our unique ‘CHA Bio ecosystem': Academic, Research, Medical Network, and Bio-Industry Business, the world's largest cell library, and our independently developed vaccine adjuvant platform. We will leap forward as a true global bio company centered on the third-generation CGT CDMO and global healthcare business.

Dong-A Pharmaceutical

Dong-A Pharmaceutical

Seoul, Korea

Dong-A ST is a company established in March 2013 following the restructuring of the former Dong-A Pharmaceutical into a holding company. Our company focuses on the development and sale of specialized pharmaceuticals (ETC) and is dedicated to the philosophy of "Our company's social contribution is in new drug development." With state-of-the-art research facilities such as the Yongin Research Center established in 1977 and the completion of the Songdo Research Center in 2021, Dong-A ST has been striving for innovative global new drug development with excellent research and development capabilities. For many years, by consistently investing more than 10% of its revenue in R&D, we have successfully developed multiple proprietary novel drugs, including Stillen, Zydena, Motilitone, Sivextro, and Suganon/Sugamet.